NCT01469247 is a Phase 1, PHASE2 clinical trial of Radiation Therapy in Brain Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01469247?

NCT01469247 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01469247?

Interventions in NCT01469247: Radiation Therapy.

What condition does NCT01469247 study?

NCT01469247 studies Brain Cancer.

Is NCT01469247 still recruiting?

NCT01469247 is currently completed. Last updated 20 October 2022.

Last reviewed 2022-10-20 · How we verify

NCT01469247

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Completed Phase 1, PHASE2 Last updated 20 October 2022

What this trial tests

Phase 1, PHASE2 trial testing Radiation Therapy in Brain Cancer in 12 participants. Completed in 20 September 2022.

Timeline

7 December 2011

Primary endpoint
20 September 2022

20 September 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	7 December 2011
Primary completion	20 September 2022
Estimated completion	20 September 2022
Sites	2 locations across United States

Drugs / interventions tested

Radiation Therapy — full drug profile →

Conditions studied

Brain Cancer — all drugs for Brain Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Under 17, any sex, with Brain Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy. This type of radiation is similar to the radiation you have already had. Conformal radiotherapy or intensity modulated radiotherapy (IMRT) will be used to try to treat the tumor while affecting as little of the surrounding normal tissue as possible.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A, Galban S. · · 2023 · cited 22× · PMID 37030112 · DOI 10.1016/j.neo.2023.100899
The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective.
Clymer J, Kieran MW. · · 2018 · cited 15× · PMID 29868485 · DOI 10.3389/fonc.2018.00169
Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Scutti JAB. · · 2018 · cited 8× · PMID 29484440 · DOI 10.3892/ijo.2018.4283
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS, Bouchal SM, Power EA, Nonnenbroich LF, et al · · 2023 · cited 3× · PMID 37897190 · DOI 10.1080/14728222.2023.2277232
Sequential Diffusion Tensor Imaging and Magnetic Resonance Spectroscopy in Patients Undergoing Reirradiation for Progressive Diffuse Intrinsic Pontine Glioma.
Bronk JK, Hou P, Amsbaugh MJ, Khatua S, et al · · 2022 · cited 1× · PMID 35071836 · DOI 10.1016/j.adro.2021.100847

Verify or expand the search:

Other trials of Radiation Therapy

Trials testing the same drug.

NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07466316 — A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Ove · Phase 3 · not yet recruiting

Other recruiting trials for Brain Cancer

Currently open trials in the same condition.

NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
NCT06058988 — Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer · Phase 2 · recruiting
NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
NCT05943262 — Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01469247 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 20 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01469247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing